United States Artificial Blood Market 2026 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

Global Artificial Blood Market reached US$ 3760.00 million in 2023 and is expected to reach US$ 7194.83 million by 2031, growing at a CAGR of 8.7% during the forecast period 2024-2031.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/artificial-blood-market?sb

Key Development:

United States: Recent Industry Developments

✅ In January 2026, a U.S. biotechnology company specializing in oxygen therapeutics completed the acquisition of a research‐stage artificial blood technology platform to accelerate clinical development and move synthetic blood substitutes closer to regulatory progress and potential human testing.

✅ In December 2025, growing interest in rapid‐response medical solutions in military, disaster relief, and remote healthcare settings drove heightened investment and focus on artificial blood technologies designed to improve oxygen delivery and shelf‐stable substitutes for donated blood.

✅ In December 2025, partnerships between academic labs and biotech firms expanded efforts to refine next‐generation hemoglobin‐based oxygen carriers, enhancing stability and performance characteristics for emergency medicine applications.

✅ In December 2025, consolidation in the advanced therapeutics sector saw strategic moves to strengthen portfolios in synthetic blood and oxygen‐carrying substitutes, supporting broader adoption of artificial blood science.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=artificial-blood-market

Japan: Recent Industry Developments

✅ In February 2026, Japanese research entered a new phase with advancements in universal artificial blood designed to be compatible with all blood types, featuring prolonged storage stability and progressing toward wider clinical application to address global blood shortages.

✅ In December 2025, Japanese institutions continued to advance artificial blood technologies centered on hemoglobin vesicles engineered oxygen carriers lacking blood‐type antigens reinforcing Japan's leadership in developing universal, virus‐free blood substitutes with longer shelf life.

✅ In December 2025, ongoing efforts in Japan focused on adapting artificial blood substitutes for emergency and critical care use, with clinical safety and efficacy evaluations progressing following expanded volunteer testing earlier in the year.

✅ In January 2026, Japanese artificial blood research maintained momentum as academic and medical centers continued preparing for later‐stage clinical trials and regulatory pathways to bring universal blood substitutes closer to practical medical use.

Key Players:

=> Hemarina, KaloCyte, Inc., SpheriTech Limited, and Hemoglobin Oxygen Therapeutics LLC among others

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/artificial-blood-market?sb

Key Segments:

By Product Type

Hemoglobin-based Oxygen Carriers (HBOCs) dominate the market with an estimated 60% share, driven by increasing adoption in trauma care, surgical procedures, and cardiovascular treatments where blood substitutes are critical.

Perfluorocarbon Emulsion accounts for 40%, supported by its usage in organ transplantation, neonatal care, and specialized therapeutic applications.

By Source

Human Hemoglobin contributes around 35%, as it provides high oxygen-carrying efficiency and is preferred in clinical applications.

Animal Hemoglobin holds 15%, mainly used in preclinical and experimental studies.

Stem Cells and Synthetic Polymers account for 25%, reflecting the rise of synthetic and bioengineered substitutes to overcome supply shortages and immune compatibility issues.

Microorganisms and Others cover 25%, representing emerging biotechnologies and recombinant platforms in oxygen carrier production.

By Process

Synthetic Production leads with 40% share, due to scalability, controlled manufacturing, and cost-effectiveness.

Chemical Isolation accounts for 30%, primarily from human and animal sources.

Recombinant Biochemical Technology contributes 30%, driven by advancements in genetic engineering, protein expression, and bio-manufacturing for clinical applications.

By Application

Anemia dominates with 30% share, owing to the high prevalence of chronic anemia and conditions requiring oxygen supplementation.

Organ Transplantation accounts for 20%, reflecting the use of oxygen carriers to preserve organs and improve transplant success rates.

Injuries & Trauma holds 15%, driven by emergency medicine and trauma centers needing rapid blood substitutes.

Cardiovascular Diseases and Maternal Conditions contribute 20%, as oxygen carriers assist in surgeries and high-risk pregnancies.

Others account for 15%, including neonatal care, research applications, and critical care interventions.

By End-User

Hospitals dominate with 50% share, as most applications for oxygen carriers are in clinical and surgical settings.

Clinics hold 15%, primarily for specialized care or outpatient procedures.

Blood Banks account for 15%, focusing on storage, research, and emergency use.

Research Institutes contribute 10%, driven by R&D in novel oxygen therapeutics.

Others hold 10%, including mobile care units and field emergency response.

By Region

North America leads with 35% share, driven by advanced healthcare infrastructure, high trauma incidence, and adoption of HBOCs in clinical practice.

Europe follows with 28%, supported by research investments, organ transplant programs, and regulatory approvals for synthetic oxygen carriers.

Asia Pacific accounts for 25%, fueled by growing hospitals, rising anemia prevalence, and increasing healthcare expenditure.

Latin America and Middle East & Africa together hold 12%, reflecting emerging adoption in trauma care and surgical applications.

Outlook & Opportunity Analysis (2024-2031)

The global blood substitute market is expected to grow steadily, driven by rising prevalence of anemia, increasing trauma cases, and organ transplantation demand. Opportunities lie in synthetic and recombinant oxygen carriers, stem cell-based production, and expansion into emerging regions with growing healthcare infrastructure.

FAQ

What is the current size of the Artificial Blood Market?

A: In 2023, the Artificial Blood Market was valued at US$ 3760.00 million, reflecting its strong industry presence.

Q2: How large is the Artificial Blood Market expected to be by 2031?

A: By 2031, industry forecasts suggest the Artificial Blood Market will grow to around US$ 7194.83 million, demonstrating significant expansion.

Q3: What is the growth rate of the Artificial Blood Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 8.7% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.